Skip to main content
Premium Trial:

Request an Annual Quote

Jay Short Resigns as CEO of Diversa; Jochen Kohlhass Joins Febit as Finance VP; MaryAnn Guerra New COO of TGen; Mahesh Krishnamurthy Leaves Post as Senior VP of Corporate Development at Accelrys; and Others

The Windber Research Institute has made a number of administrative changes, GenomeWeb News has learned. Richard Mural joined the institute as chief scientific officer in September, replacing Michael Liebman, who has become executive director. In the past, Mural was director of scientific content and analysis at Celera Genomics.


Further, Michael Dunn joined Windber as its first chief medical officer in July. He is a retired brigadier general.


Richard Somiari has left his post as chief scientific officer and chief executive officer to found his own company (see below).

Richard Somiari has become president and chief scientific officer of Integrated Technologies & Services International - Biosciences in Johnstown, Pa., his own company, GenomeWeb News has learned. He used to be chief scientific officer and chief operating officer of the Windber Research Institute. Somiari holds a PhD in biochemistry from the Technical University of Lodz, Poland, an MSc in food science & technology from Obaferri Awolowo University in Ile Ife, Nigeria, and a BSc in applied biology from the University of Science & Technology in Port Harcourt, Nigeria.

Jochen Kohlhaas has become vice president for finance of Febit Biotech, the Heidelberg, Germany-based company said today. He holds a degree in business administration.


Further, the company established a supervisory board and appointed the following members: Gerald Möller, former president and chief executive officer of Boehringer Mannheim; Michael Kranich, CEO of DH-Capital and OH Beteiligungen; Christof Hettich, a lawyer at Rittershaus; and Michael Meyer, CEO of Technostart.

MaryAnn Guerra has been promoted to chief operating officer of the Translational Genomics Research Institute of Phoenix, Ariz., TGen said yesterday. Previously, she was TGen's senior vice president of operations. Prior to that, she was executive vice president of the Matthews Media Group. Guerra holds a BA in communications from Ohio State University and an MBA in Science, Innovation, and Technology from George Washington University.

Robert Young has been appointed to the board of directors of Human Genome Sciences, the company said today. He is the president of the Fox Chase Cancer Center in Philadelphia. Young holds an MD from Cornell University Medical College and a BSc in zoology from Ohio State University.

Daniel Von Hoff has joined the oncology advisory board of Locus Pharmaceuticals, the Blue Bell, Pa.-based company said yesterday. He is the director of translational research at the Translational Genomics Research Institute in Arizonaand a clinical professor of medicine at the Universityof Arizona.

Mahesh Krishnamurthy left his post as senior vice president of corporate development of Accelrys this summer, the company said in an SEC filing yesterday. A separation agreement with Krishnamurthy from October determines that he will receive $117,500 and reimbursement for up to six months for premiums paid for medical, dental, and vision insurance coverage.

Jennifer Gordon and Scott Familant have joined the intellectual property group in New Yorkof Sidley Austin Brown & Wood as partners, the company said yesterday. Both have represented pharmaceutical and biotechnology companies, including in actions in the USand abroad to enforce patents on PCR technology. Gordon holds a PhD in life sciences and biochemical engineering from MIT and a JD from FordhamUniversity School of Law. Familant holds a bachelor's degree in chemistry from CornellUniversityand a JD from George Washington University.

Evan Steeghas become a contractor for senior strategy and business development at CMC Microsystems, GenomeWeb News has learned. He will help to lead the non-profit corporation further into healthcare and life sciences applications and partnerships. Previously, Steeg was president and CEO of Molecular Mining.

As part of Alpha Innotech's recent reverse merger with Xtrana, Haseeb Chaudhry has become chief executive officer and Darryl Ray president, chief operating officer, and acting chief financial officer of the merged company, Alpha Innotech. The following were appointed as members of the board of directors: Haseeb Chaudhry, Darryl Ray, Nagesh Mhatre, and William Snider. In addition, two continuing directors of Xtrana, Michael Bick and James Chamberlain, have joined the board.

Shirley Tilghman, PrincetonUniversity's president and professor of molecular biology, has been appointed to the board of directors of Google. Tilghman was a member of the National Research Council committee that guided the USeffort in the Human Genome Project and was a founding member of the National Advisory Council of the Human Genome Project Initiative for the National Institutes of Health. She was also the founding director of Princeton's multi-disciplinary Lewis-Sigler Institute for Integrative Genomics and became the university's president in June 2001.

In conjunction with the recent acquisition of Genaissance Pharmaceuticals by Clinical Data, Kevin Rakin and Joseph "Skip" Klein III have joined the board of directors of Clinical Data, the company said last week. Both were directors of Genaissance.

Jay Short has resigned as president and CEO of Diversa and has stepped down from the company's board, the San Diego-based company said last week. Edward Shonsey, Diversa's executive vice president of internal development, has been appointed as interim CEO.

Michael McGarrity has joined Nanosphere as chief marketing officer, the Northbrook, Ill.-based company said last week. He will help Nanosphere as it prepares to commercialize its Verigene platform for the detection of proteins and nucleic acids. McGarrity comes to Nanosphere from Stryker, where he was vice president of marketing for the Stryker Instruments division. He holds a degree from the Universityof Notre Dame.

Wylie Chenn has become regional director Asia/Pacific for Serologicals, the Atlanta, Ga.-based company said last week. He will work for the company's three business units, Celliance, Chemicon International, and the Upstate Group. Most recently, Chenn was general manager for the BioScience division, Asia Pacific, China Operations for Fisher Scientific. Chenn, who will be based in Hong Kong, holds an MBA in finance and economics from the Universityof Washingtonand a bachelor of science in marketing and international business from Brigham Young University.

David Gelfand has retired as vice president of the discovery research division and director of the program in core research of Roche Molecular Systems, GenomeWeb News has learned. He was based at Roche Molecular in Alameda, Calif.

Promoted? Changing jobs?GenomeWeb News wants to know. E-mail us at   [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.